Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.47 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.47 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.46 |
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.42 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 known ✓ | P08238 | 1/20 | 0.42 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | PEPD | P12955 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | MB | P02144 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9745051 | 1.00 | CYP1A1 (0.52) | CYP1A1HIF1AMAOAMAOBCA2 | |
| SCHEMBL22354 | 1.00 | CYP1A1 (0.52) | CYP1A1HIF1AMAOAMAOBCA2 | |
| SCHEMBL9743702 | 1.00 | CYP1A1 (0.52) | CYP1A1HIF1AMAOAMAOBCA2 | |
| Hydrochloric Acid SCHEMBL11326485 | 1.00 | CYP1A1 (0.52) | CYP1A1HIF1AMAOAMAOBCA2 | |
| SCHEMBL9745182 | 1.00 | CYP1A1 (0.52) | CYP1A1HIF1AMAOAMAOBCA2 | |
| Benzene SCHEMBL11193867 | 0.98 | CYP1A1 (0.50) | CYP1A1HIF1AMAOAMAOBCA2 | |
| Ammonia Solution, Strong SCHEMBL10883600 | 0.98 | CYP1A1 (0.50) | CYP1A1HIF1AMAOAMAOBCA2 | |
| SCHEMBL11973849 | 0.98 | CYP1A1 (0.50) | CYP1A1HIF1AMAOAMAOBCA2 | |
| SCHEMBL1578385 | 0.98 | CYP1A1 (0.50) | CYP1A1HIF1AMAOAMAOBCA2 | |
| Hypochlorous Acid SCHEMBL11320999 | 0.96 | CYP1A1 (0.48) | CYP1A1HIF1AMAOAMAOBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427692-B2 | Process for preparation of 7-[α-amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid | LUPIN LTD. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7230097-B2 | Process for preparation of 7-[α-Amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid | LUPIN LTD. (IN) | 2007-06-12 | — | — | US | disclosed |
| US-20060149096-A1 | Process for preparation of 7-[a-amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid | LUPIN LTD. (IN) | 2006-07-06 | — | — | US | disclosed |
| US-20050113570-A1 | Process for preparation of 7-[alpha-amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid | LUPIN LTD. (IN) | 2005-05-26 | — | — | US | disclosed |
| WO-2002068428-A1 | METHOD OF PREPARING CEPHALOSPORINS USING 4-HYDROXYPHENYLGLYCINE DERIVATIVES | HANMI PHARM. CO., LTD. (KR) | 2002-09-06 | — | — | WO | disclosed |
| US-20020120136-A1 | Method of preparing cephalosporins using 4-hydroxyphenylglycine derivatives | HANMI PHARM. CO., LTD. (KR) | 2002-08-29 | — | — | US | disclosed |
| CN-1024417-C | Preparation method of 3-triazolyl-thiomethyl cephem-4-carboxylic acid 1, 2-propylene glycol ester | BIOCHIMICA OPAS SPA (IT) | 1994-05-04 | — | — | CN | disclosed |
| US-4965355-A | Process for the prepartion of cefatrizine 1,2-propylene glycolate | BIOCHIMICA OPOS SPA (IT) | 1990-10-23 | — | — | US | disclosed |
| US-4694079-A | CRYSTALLINE DIMETHYLFORMAMIDE SOLVATE | BRISTOL-MYERS COMPANY (US) | 1987-09-15 | — | — | US | disclosed |
| EP-0001133-B1 | PROCESS FOR THE PREPARATION OF 6- D-ALPHA-AMINO-(P-HYDROXYPHENYL)-ACETAMIDO PENICILLANIC ACID | GIST-BROCADES N.V. (NL) | 1982-01-20 | — | — | EP | disclosed |
| US-4310460-A | Process for the production of 6-D-α-amino-p-hydroxyphenylacetamido penicillanic acid | DOBFAR S.P.A. (IT) | 1982-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113570-A1 | Process for preparation of 7-[alpha-amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid | IGLV6-57, APC, HBZ | MAOA 332/4885MAOB 1611/4885CA2 1375/4885 |
| US-20020120136-A1 | Method of preparing cephalosporins using 4-hydroxyphenylglycine derivatives | GYPA, PEPD, HPD | MAOA 1337/4885MAOB 1199/4885CA2 3533/4885 |
| US-20060149096-A1 | Process for preparation of 7-[a-amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid | IGLV6-57, APC, IL2 | MAOA 237/4885MAOB 1402/4885CA2 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.